Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis

P. Portincasa, V. Palmieri, F. Doronzo, G. Vendemiale, E. Altomare, C. Sabbà, G. Palasciano, O. Albano

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The short-term ability of tauroursodeoxycholic acid (TUDCA) to lower the blood levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) in patients with hypertransaminasemia and chronic active hepatitis was assessed in a 3-month, randomized, controlled clinical trial. A total of 53 patients with histologic evidence of chronic active hepatitis in a liver biopsy sample and an increase in the serum values of ALT of at least twice the upper limit of normal in two separate checkups in the previous 6 months were enrolled in the study. TUDCA 500 mg/day divided into two doses with meals was given to 27 patients; the remaining 26 patients served as controls. Follow-ups were performed in both the treated and control patients at 1 month, 2 months, and the end of the study period. All patients completed the study. The effect of TUDCA on liver serum enzymes was evident after 1 month and reached a maximum effect after 3 months, when TUDCA had significantly lowered AST (-44%), ALT (-49%), and GGT (-38%) (P <0.001, compared with baseline values). Throughout the study, serum levels of alkaline phosphatase and bilirubin remained within a normal range in all patients. A spontaneous slight decrease in AST (11% to 14%), ALT (13% to 15%), and GGT (5% to 7%) was observed in the control group during the study. None of the patients receiving TUDCA reported side effects. Dyspeptic symptoms were evident in 70% of the TUDCA patients and 62% of the controls and were individually scored at the beginning of the trial. After 3 months, the score decreased significantly in the TUDCA group but not in the control group (P <0.001). Short-term therapy with TUDCA is effective in lowering serum levels of transaminases and GGT, is free of hepatotoxic effects, and improves dyspeptic symptoms in patients with chronic active hepatitis. Further studies are needed to investigate the influence of TUDCA therapy on the natural history of chronic active hepatitis.

Original languageEnglish
Pages (from-to)521-532
Number of pages12
JournalCurrent Therapeutic Research
Volume53
Issue number5
DOIs
Publication statusPublished - 1993

Fingerprint

Chronic Hepatitis
Liver
Enzymes
Serum
gamma-Glutamyltransferase
Alanine Transaminase
Aspartate Aminotransferases
tauroursodeoxycholic acid
Control Groups
Transaminases
Bilirubin
Alkaline Phosphatase
Meals
Reference Values
Randomized Controlled Trials
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis. / Portincasa, P.; Palmieri, V.; Doronzo, F.; Vendemiale, G.; Altomare, E.; Sabbà, C.; Palasciano, G.; Albano, O.

In: Current Therapeutic Research, Vol. 53, No. 5, 1993, p. 521-532.

Research output: Contribution to journalArticle

Portincasa, P, Palmieri, V, Doronzo, F, Vendemiale, G, Altomare, E, Sabbà, C, Palasciano, G & Albano, O 1993, 'Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis', Current Therapeutic Research, vol. 53, no. 5, pp. 521-532. https://doi.org/10.1016/S0011-393X(05)80659-9
Portincasa, P. ; Palmieri, V. ; Doronzo, F. ; Vendemiale, G. ; Altomare, E. ; Sabbà, C. ; Palasciano, G. ; Albano, O. / Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis. In: Current Therapeutic Research. 1993 ; Vol. 53, No. 5. pp. 521-532.
@article{81fddbffbacb4b178b91193d7c8744a0,
title = "Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis",
abstract = "The short-term ability of tauroursodeoxycholic acid (TUDCA) to lower the blood levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) in patients with hypertransaminasemia and chronic active hepatitis was assessed in a 3-month, randomized, controlled clinical trial. A total of 53 patients with histologic evidence of chronic active hepatitis in a liver biopsy sample and an increase in the serum values of ALT of at least twice the upper limit of normal in two separate checkups in the previous 6 months were enrolled in the study. TUDCA 500 mg/day divided into two doses with meals was given to 27 patients; the remaining 26 patients served as controls. Follow-ups were performed in both the treated and control patients at 1 month, 2 months, and the end of the study period. All patients completed the study. The effect of TUDCA on liver serum enzymes was evident after 1 month and reached a maximum effect after 3 months, when TUDCA had significantly lowered AST (-44{\%}), ALT (-49{\%}), and GGT (-38{\%}) (P <0.001, compared with baseline values). Throughout the study, serum levels of alkaline phosphatase and bilirubin remained within a normal range in all patients. A spontaneous slight decrease in AST (11{\%} to 14{\%}), ALT (13{\%} to 15{\%}), and GGT (5{\%} to 7{\%}) was observed in the control group during the study. None of the patients receiving TUDCA reported side effects. Dyspeptic symptoms were evident in 70{\%} of the TUDCA patients and 62{\%} of the controls and were individually scored at the beginning of the trial. After 3 months, the score decreased significantly in the TUDCA group but not in the control group (P <0.001). Short-term therapy with TUDCA is effective in lowering serum levels of transaminases and GGT, is free of hepatotoxic effects, and improves dyspeptic symptoms in patients with chronic active hepatitis. Further studies are needed to investigate the influence of TUDCA therapy on the natural history of chronic active hepatitis.",
author = "P. Portincasa and V. Palmieri and F. Doronzo and G. Vendemiale and E. Altomare and C. Sabb{\`a} and G. Palasciano and O. Albano",
year = "1993",
doi = "10.1016/S0011-393X(05)80659-9",
language = "English",
volume = "53",
pages = "521--532",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis

AU - Portincasa, P.

AU - Palmieri, V.

AU - Doronzo, F.

AU - Vendemiale, G.

AU - Altomare, E.

AU - Sabbà, C.

AU - Palasciano, G.

AU - Albano, O.

PY - 1993

Y1 - 1993

N2 - The short-term ability of tauroursodeoxycholic acid (TUDCA) to lower the blood levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) in patients with hypertransaminasemia and chronic active hepatitis was assessed in a 3-month, randomized, controlled clinical trial. A total of 53 patients with histologic evidence of chronic active hepatitis in a liver biopsy sample and an increase in the serum values of ALT of at least twice the upper limit of normal in two separate checkups in the previous 6 months were enrolled in the study. TUDCA 500 mg/day divided into two doses with meals was given to 27 patients; the remaining 26 patients served as controls. Follow-ups were performed in both the treated and control patients at 1 month, 2 months, and the end of the study period. All patients completed the study. The effect of TUDCA on liver serum enzymes was evident after 1 month and reached a maximum effect after 3 months, when TUDCA had significantly lowered AST (-44%), ALT (-49%), and GGT (-38%) (P <0.001, compared with baseline values). Throughout the study, serum levels of alkaline phosphatase and bilirubin remained within a normal range in all patients. A spontaneous slight decrease in AST (11% to 14%), ALT (13% to 15%), and GGT (5% to 7%) was observed in the control group during the study. None of the patients receiving TUDCA reported side effects. Dyspeptic symptoms were evident in 70% of the TUDCA patients and 62% of the controls and were individually scored at the beginning of the trial. After 3 months, the score decreased significantly in the TUDCA group but not in the control group (P <0.001). Short-term therapy with TUDCA is effective in lowering serum levels of transaminases and GGT, is free of hepatotoxic effects, and improves dyspeptic symptoms in patients with chronic active hepatitis. Further studies are needed to investigate the influence of TUDCA therapy on the natural history of chronic active hepatitis.

AB - The short-term ability of tauroursodeoxycholic acid (TUDCA) to lower the blood levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) in patients with hypertransaminasemia and chronic active hepatitis was assessed in a 3-month, randomized, controlled clinical trial. A total of 53 patients with histologic evidence of chronic active hepatitis in a liver biopsy sample and an increase in the serum values of ALT of at least twice the upper limit of normal in two separate checkups in the previous 6 months were enrolled in the study. TUDCA 500 mg/day divided into two doses with meals was given to 27 patients; the remaining 26 patients served as controls. Follow-ups were performed in both the treated and control patients at 1 month, 2 months, and the end of the study period. All patients completed the study. The effect of TUDCA on liver serum enzymes was evident after 1 month and reached a maximum effect after 3 months, when TUDCA had significantly lowered AST (-44%), ALT (-49%), and GGT (-38%) (P <0.001, compared with baseline values). Throughout the study, serum levels of alkaline phosphatase and bilirubin remained within a normal range in all patients. A spontaneous slight decrease in AST (11% to 14%), ALT (13% to 15%), and GGT (5% to 7%) was observed in the control group during the study. None of the patients receiving TUDCA reported side effects. Dyspeptic symptoms were evident in 70% of the TUDCA patients and 62% of the controls and were individually scored at the beginning of the trial. After 3 months, the score decreased significantly in the TUDCA group but not in the control group (P <0.001). Short-term therapy with TUDCA is effective in lowering serum levels of transaminases and GGT, is free of hepatotoxic effects, and improves dyspeptic symptoms in patients with chronic active hepatitis. Further studies are needed to investigate the influence of TUDCA therapy on the natural history of chronic active hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=0027328919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027328919&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80659-9

DO - 10.1016/S0011-393X(05)80659-9

M3 - Article

AN - SCOPUS:0027328919

VL - 53

SP - 521

EP - 532

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -